Oppenheimer assigned Kursziel for Cellectar Biosciences to an Outperform-Rating of Q3-Finanzen from Investing.com.

Oppenheimer outperformed the $12.00 Kursziel for Cellectar Biosciences (NASDAQ:CLRB), which carries an Outperform Rating from Aktie. Company Analyst is a current company updated to Grund für die Anpassung.

Montag provides Cellectar Biosciences’ Financial and Geschäfts updates for the fourth quarter. Among the best tags regarding Das unternehmen gab bekannt, dass new Daten zur Iopofosine I131-Behandlung für Morbus Waldenström (WM) American Society of Hematology (ASH) took place on 09.12.2023.

A study was conducted by the United States Food and Drug Administration (FDA), which is considered one of the best scientific studies. Discussions were evaluated regarding the Einreichung des Zulassungsantrags (New Drug Application, NDA), covering the last quarter of 2025 through the quarter of 2024.

Der Analyst von Oppenheimer enabled Cellectar to further benefit from Behandlung der Zulassung. The current company model, which is a financially good company model, has passed an up-to-date planning with a financial forecaster in 2024. Kursziels was evaluated based on Cellectar Biosciences’ Outstanding Performance Rating.

Cellectar Biosciences has faced a new investment as a new source of financing, as one of the Securities and Exchange Commission’s (SEC) top filings.

For Cellectar to develop a strategy with a 10-jährige Versorgung between NorthStar Medical Radioisotopes and Actinium-225, we use CLR 121225-Entwicklungsprogramm. Dieses Programm, das sich gezelte Therapien für solid Tumor konzentriert, die klinische Erprobung gehen in 2025.

Cellectar has a new Zulassungsantrag of Iopofosine I 131 for a new Quarter 2024 year. A study by Morbus Waldenström showed a Gesamtansprechrate of 80% and a clinical Nutzenrate of 98.2%.

Oppenheimer has a financial analysis of Cellectar Biosciences with an Outperform rating. Following Cellectars, a new podium discussion of Oppenheimers took place at the Targeted Radiopharmaceuticals Summit.

For further information, clinical studies have been conducted on Iopofosine for other hematological indications and a Phase-1 Study on Biosciences’ Phospholipid Drug Conjugate (PDC) Platform. Diese jüngsten Entwicklungen unterstreichen den Fortschritt des Unternehmens in the biopharmaceutical sector.

InvestingPro Erkenntnisse

Aktuelle Investing Pro Data provides content regarding the financial situation and Marktleistung provided by Cellectar Biosciences (NASDAQ:CLRB). Unternehmens Marktkapitalisierung worth US$ 63.45 Million was spread more widely in the Biotechnology Sector.

InvestingPro-Tipps, CLRB more Bargeld als Schulden’s Bilanz hat, Finanzierung seiner laufenden und Entwicklungsanstrengungen für Forschungs- und Entwicklungsanstrengungen, was a Iopofosine I131-Behandlung für, entscheidend sein könnte for Morbus Waldenström. Allerdings Verrennt das Unternehmen Schnell Bargeld was a typical Entrepreneurial Stage Biotechnology-Unternehmen.

Current Performance, Everything is going well with Artikel. InvestingPro-Data shows that CLRB has a yield of 17.29 percent and a yield of 46.36 percent. During the past period, there has been no activity with an amount between 39.78 percent of 52-Wochen-Hochs and 52-Wochen-Hochs.

Both currencies have had a long-term analysis with a fair Ausblick of $12.00 per current transaction of $1.77. He dies with the Oppenheimers having a better performance plan for the NDA-Einreichung.

Für Investoren, die eine umfassendere Analysis such a, bietet InvestmentPro 13 A few tips for CLRB, many versions of financial markets and the position of the global market.

Diese Übersetzung wurde mithilfe künstlicher Intelligenz erstellt. Learn more about some information.